Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data
Provided By PR Newswire
Last update: Jul 20, 2022
Dose optimization prepares the Company for its next phase of Bryostatin clinical development
Company expects to announce topline data from its NIH sponsored Phase 2 clinical study during the fourth quarter of 2022
Read more at prnewswire.com
